Ajanta Pharma Ltd
NSE:AJANTPHARM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Ajanta Pharma Ltd
Inventory
Ajanta Pharma Ltd
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Ajanta Pharma Ltd
NSE:AJANTPHARM
|
Inventory
₹8.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
5%
|
CAGR 10-Years
17%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Inventory
₹75.8B
|
CAGR 3-Years
16%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Inventory
₹61.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Inventory
₹104.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Inventory
₹59.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Inventory
₹24.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
7%
|
|
Ajanta Pharma Ltd
Glance View
In the bustling landscape of the Indian pharmaceutical industry, Ajanta Pharma Ltd. has carved a niche for itself with a blend of strategic innovation and market smartness. Founded in 1973, the company swiftly harnessed the dynamics of a growing market by focusing on specialty therapeutic segments including cardiology, dermatology, ophthalmology, and pain management. With a distinctive approach that merges global aspirations with local market insights, Ajanta Pharma has established itself as a significant player not just in India, but also across over 30 countries. The company's success is driven by its sustained emphasis on research and development, which fuels its capabilities to roll out new, affordable formulations addressing unmet medical needs. Ajanta Pharma’s business model thrives on a two-pronged strategy: focusing on high-growth emerging markets and capitalizing on the constantly evolving healthcare demands in regulated markets like the United States. The company's adeptness at manufacturing efficiency and its vertically integrated operations enable it to maintain competitive cost structures, delivering value through robust margins. The revenue streams are further amplified by its prowess in developing generic drugs for the American market, where it navigates through complex regulatory landscapes to outpace competitors. Underpinned by a strong commitment to quality and patient-centric innovation, Ajanta Pharma’s operations exemplify a balanced growth trajectory, reinforcing its status as a dynamic and responsive healthcare entity.
See Also
What is Ajanta Pharma Ltd's Inventory?
Inventory
8.1B
INR
Based on the financial report for Dec 31, 2025, Ajanta Pharma Ltd's Inventory amounts to 8.1B INR.
What is Ajanta Pharma Ltd's Inventory growth rate?
Inventory CAGR 10Y
17%
Over the last year, the Inventory growth was -4%. The average annual Inventory growth rates for Ajanta Pharma Ltd have been 3% over the past three years , 5% over the past five years , and 17% over the past ten years .